The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can ach ...

Consolidated Lithium Metals Inc. (TSXV: CLM | FRA: Z36) ("CLM" or the "Company") is pleased to announce that it has entered into on November 17, 2025 a binding ...

Upon satisfaction of these conditions and acquisition by the Company of the initial 60% undivided interest in the Project, CLM and SOQUEM will form a joint venture in respect of the Project to be ...